Research Topics
Species | Stephen A CannistraSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra
Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 25:5180-6. 2007....- Cancer of the ovaryStephen A Cannistra
Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
N Engl J Med 351:2519-29. 2004 - Unique gene expression profile based on pathologic response in epithelial ovarian cancerDimitrios Spentzos
Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Oncol 23:7911-8. 2005..Efforts to identify a more tailored profile using selected genes from both the CRP and OCPP are underway... 
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancerPanagiotis A Konstantinopoulos
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Clin Oncol 28:3555-61. 2010..To define a gene expression profile of BRCAness that correlates with chemotherapy response and outcome in epithelial ovarian cancer (EOC)...
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancerPanagiotis A Konstantinopoulos
Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Cancer Res 71:5081-9. 2011..Our findings identify Keap1 mutations in EOC and they suggest a previously unrecognized role for the Keap1-Nrf2 pathway in mediating chemotherapeutic responses in this disease...- IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancerDimitrios Spentzos
Gynecologic Medical Oncology Program, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Endocr Relat Cancer 14:781-90. 2007..Future studies are needed to more precisely determine the diagnostic and potential therapeutic significance of these findings... - A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerAnna Berkenblit
Dana-Farber/Harvard Cancer Center Program in Gynecologic Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Gynecol Oncol 95:624-31. 2004..A starting docetaxel dose of 30 mg/m(2) would be reasonable for future studies exploring the utility of weekly dosing in less heavily pre-treated patients... - Gene expression signature with independent prognostic significance in epithelial ovarian cancerDimitrios Spentzos
Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Oncol 22:4700-10. 2004.... - Gene-expression profiling in epithelial ovarian cancerPanagiotis A Konstantinopoulos
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Nat Clin Pract Oncol 5:577-87. 2008..In this Review, we summarize the contributions of gene-expression profiling to the diagnosis and management of epithelial ovarian cancer and discuss ways in which this technique could become a useful tool in clinical management... - Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancerJo Marie Tran Janco
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Minim Invasive Gynecol 18:629-33. 2011..To evaluate complications of intraperitoneal ports placed laparoscopically as a separate procedure after initial debulking surgery for ovarian, fallopian tube, or primary peritoneal cancer... - Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancerPanagiotis A Konstantinopoulos
Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 6:e18202. 2011..Public data integration may help overcome challenges in clinical implementation of microarray profiles. We integrated several ovarian cancer datasets to identify a reproducible predictor of survival... - Advances in the management of epithelial ovarian cancerAnna Berkenblit
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
J Reprod Med 50:426-38. 2005.... - Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerUrsula A Matulonis
Department of Medical Oncology, Dana Farber Cancer Institute, MA 02115, USA
J Clin Oncol 27:5601-6. 2009..Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit... - The ethics of early stopping rules: who is protecting whom?Stephen A Cannistra
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
J Clin Oncol 22:1542-5. 2004 - Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian originAnna Berkenblit
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Gynecol Oncol 89:486-93. 2003..CONCLUSIONS: The DoCaGem regimen is highly active, but myelosuppression at dose level I prevents full dose delivery. Other strategies to combine these three active agents are reasonable to explore... - Progress in the management of gynecologic cancer: consensus summary statementStephen A Cannistra
Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
J Clin Oncol 21:129s-132s. 2003 - Granulosa cell tumor of the ovarySusan Tinsley Schumer
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Clin Oncol 21:1180-9. 2003..Because of the propensity of GCT to recur years after initial diagnosis, prolonged surveillance with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonable... - BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary diseaseStephen A Cannistra
Clin Cancer Res 13:7225-7. 2007 - Challenges and pitfalls of combining targeted agents in phase I studiesStephen A Cannistra
J Clin Oncol 26:3665-7. 2008 - Intraperitoneal chemotherapy comes of ageStephen A Cannistra
N Engl J Med 354:77-9. 2006 - Gynecologic oncology or medical oncology: what's in a name?Stephen A Cannistra
J Clin Oncol 25:1157-9. 2007 - Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?Stephen A Cannistra
J Clin Oncol 20:1158-60. 2002